Forward-looking statements relate to the date initially made and Kohl's Corporation undertakes no obligation to update them. With me this morning are Michael Bender, our Chief Executive Officer, and ...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...